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Background: While there have been studies in adults reporting discordant empiric antibiotic 
treatment associated with poor outcomes, this area is relatively unexplored in children and 
neonates despite evidence of increasing resistance to recommended first-line treatment regimens.  
 
Methods: Patient characteristics, antibiotic treatment, microbiology and 30-day all-cause outcome 
from children <18 years with blood-culture-confirmed bacterial BSI were collected anonymously 
using REDCap™ through the Global Antibiotic Prescribing and Resistance in Neonates and Children 
(GARPEC) network from February 2016-February 2017. Concordance of early empiric antibiotic 
treatment was determined using EUCAST interpretive guidelines. The relationship between 
concordance of empiric regimen and 30-day mortality was investigated using multivariable 
regression. 
 
Results: 452 children with blood-culture-positive BSI receiving early empiric antibiotics were 
reported by 25 hospitals in 19 countries. 60% (273/452) were under the age of 2 years. S. aureus, E. 
coli and Klebsiella spp. were the most common isolates and there were 158 unique empiric regimens 
prescribed. 15.3% (69/452) of patients received a discordant regimen and 7.7% (35/452) died. 6% 
(23/383) of patients with concordant regimen died compared to 17.4% (12/69) of patients with 
discordant regimen. Adjusting for age, sex, presence of comorbidity, unit type, HAI and Gram stain, 
the odds of 30-day mortality were 2.9 (95%CI:1.2-7.0, p=0.015) for patients receiving discordant 
early empiric antibiotics.  
 
Conclusions: Odds of mortality in confirmed paediatric BSI are nearly 3-fold higher for patients 
receiving a discordant early empiric antibiotic regimen. The impact of improved concordance of early 









There is a common understanding that rapidly treating bloodstream infections with appropriate 
antibiotic therapy  can reduce morbidity and mortality.(1–4) Generally, inappropriate treatment in 
this context is defined as the cultured bacterial isolate being resistant to the empirically 
administered antibiotic or antibiotic combination. Early empiric treatment tends to be based on 
clinical presentation until microbiology results are known which can take several days.(5) Most 
studies that have found an association between discordant empiric antibiotic therapy and mortality 
have been conducted in sepsis or bloodstream infection in adults.(1,4) In contrast, there are limited 
data in neonates and children.  
Currently, the World Health Organisation (WHO) universally recommends empiric first line therapy 
of ampicillin and gentamicin for suspected sepsis in neonates and children which does not account 
for the wide variation in resistance patterns seen globally.(6,7) With the rise of antimicrobial 
resistance, there is concern that clinicians will empirically prescribe combinations of broader-
spectrum antibiotics aiming to reduce poor outcomes, in turn, increasing patient and unit level 
exposure.(8) 
To determine the importance of concordance of empiric regimens for children, a clearer 
understanding of the relationship between discordant empiric regimens and adverse clinical 
outcomes is required. This study aims to explore the association between discordant empiric 
antibiotic therapy and 30-day all-cause mortality in children and neonates globally.  
Materials and Methods 
Study design and study population 
A retrospective observational cohort study analysing data collected via the Global Antibiotic 
Resistance, Prescribing and Efficacy in Neonates and Children (GARPEC) network was performed to 
address the study objectives. The GARPEC network aimed to provide tools for surveillance of 
antibiotic prescribing and resistance data in hospitalised neonates and children.(9) Data on neonates 




February 2017 were collected. Patients <18 years of age with a positive blood culture with a 
pathogen from a predefined list were included. Positive cultures of the same organism grown within 
4 weeks of the initial enrolment culture were considered part of the same episode and were not 
recorded.  
Data collection 
Demographics, comorbidities, antibiotic treatment (dose, route of administration, treatment 
duration), routine antimicrobial susceptibility testing results, and 30-day all-cause outcome data 
were anonymously collected by participating centres using REDCap™ electronic data capture tools 
hosted at St. George’s University of London. REDCap™ (Research Electronic Data Capture) is a secure 
web-based application for online data entry.(10,11) Data were collected voluntarily and sites 
received no financial incentive. All sites requiring local ethics approval received it prior to the start of 
data collection.  
Data Management 
Only patients with a monomicrobial bacterial infection were included in the final analyses.  
In GARPEC, the starting and stopping of antibiotics for neonates and children contributing to the 
bloodstream infection dataset were recorded by calendar dates only rather than by exact date and 
time, and date that speciation/susceptibility of the organism was known was not recorded. Empiric 
antibiotic treatment was therefore classified using antibiotic start and end calendar dates and date 
blood culture was taken. Conservatively, we assumed a two-day window after blood culture for 
empiric therapy during which any antibiotic treatment given would be highly unlikely to be guided 
by full microbiology results.(5) Any antibiotics received during this window were considered as 
empiric therapy, even if they were initiated during the second day after blood culture. In addition, 
we considered the first regimen to be antibiotics started at the time of blood culture or up to 1 day 
after blood culture.  
European Committee on Antimicrobial Susceptibility Testing (EUCAST) expert rules and interpretive 




• If the bacterial species is considered intrinsically resistant to a prescribed antibiotic 
according to EUCAST, susceptibility was coded as resistant regardless of reported testing 
results.  
• Primarily, if data were available for the specific antibiotic in the prescribed treatment 
regimen, this was used to determine susceptibility.  
• If a prescribed antibiotic was not tested, susceptibility results of antibiotics from the same 
class were used, for example susceptibility of an isolate to other aminoglycosides used to 
determine gentamicin susceptibility if gentamicin was not tested directly. 
• Susceptibility to third-generation cephalosporins was based on cefotaxime or ceftriaxone, 
where available. If cefotaxime and ceftriaxone were not tested, susceptibility data from 
other third-generation cephalosporins was used.  
• Susceptibility of S. aureus to broader-spectrum beta-lactams - cephalosporins and 
carbapenems - was derived from cefoxitin or oxacillin resistance, where available.  
• Susceptibility reported as intermediate was considered resistant.  
 
Empiric antibiotic regimen concordance was based on in vitro susceptibility findings. An antibiotic 
regimen was defined as concordant if the pathogen was susceptible to at least one antimicrobial in 
the empiric regimen. An antibiotic regimen was defined as discordant if the pathogen was not 
susceptible to any antibiotic in the empiric regimen. Patients with unclassifiable regimens, defined as 
unknown susceptibility of the pathogen to all empiric antibiotics or resistance of the pathogen to 
one antibiotic and unknown susceptibility  for the other antibiotic(s) were excluded from analyses.  
For the first empiric regimen, patients receiving no antibiotics up to 1 day after blood culture were 
considered part of the discordant group. We also examined these patients as a separate group.  
The primary exposure of interest was concordance of the empiric antimicrobial regimen. The 
primary outcome was 30-day all-cause mortality. Age was grouped using International Conference 




born at <37 weeks gestation were defined as preterm neonates. Babies <28 days postnatal age at 
enrolment who were born at ≥37 weeks gestation were defined as term neonates. Due to a lack of 
sub-categories for perinatal comorbidities, it was assumed comorbidities classified as “perinatal” 
included prematurity; thus to prevent prematurity being controlled for twice for pre-term neonates, 
those with only one comorbidity classified as “perinatal” were not considered as having a 
comorbidity since their age group already accounted for their prematurity. Patients in all other age 
groups with a comorbidity classified as “perinatal” were considered to have at least one comorbidity 
(e.g. infants outside of the neonatal period at enrolment who had been born prematurely). Presence 
of any other comorbidity category was counted as presence of a comorbidity for all age groups. 
Hospital-acquired infections (HAI) were considered those with positive blood culture taken two or 
more days after date of admission as exact admission and antibiotic start times were unavailable. 
Given small sample size, we did not adjust for hospital or pathogen. Patients with incomplete data 
for concordance, primary outcome and relevant covariates were excluded from final analyses.  
Statistical Analyses  
Descriptive results were examined as relative frequency, and characteristics of survivors and non-
survivors were compared using χ2 tests. Univariate Cochran-Mantel-Haenszel odds ratios for 30-day 
all-cause mortality were calculated for discordance and potential confounders.  
Multivariable logistic regression was used to investigate the relationship between the concordance 
of the empiric antibiotic regimen and 30-day all-cause mortality. Potential confounders were 
selected for inclusion in the logistic regression a priori and based on results of univariate analyses. 
After running the a priori multivariable model, any variables not statistically significantly associated 
with mortality were removed for our final model. Both a priori and final models are presented. A p-
value <0 .05 was considered as statistically significant. All analyses were done in Stata (v14.2, 
StataCorps, USA) 
Results 




The final sample size was 452 patients receiving empiric antibiotics in the first two days post-blood 
culture. When considering empiric regimens on the first day post blood culture only, there were 451 
patients (Figure, Supplemental Digital Content 1), of which 34 did not receive any antibiotics on the 
first day.  
Overall, 60% of patients (273/452) were under the age of two years, of which half (141/273) were 
infants and children between 30 days and 2 years (overall: 141/452, 31.2%) and a quarter (70/273) 
were preterm neonates (overall 70/452, 15.5%). Patients came from 25 hospitals in 19 countries 
(Supplemental Digital Content 2, table). Healthcare-associated infections accounted for 47.6% 
(215/452) of infections. Baseline characteristics of survivors and non-survivors are summarised in 
Table 1. Overall, 62.2% (281/452) patients had at least one comorbidity of which the most common 
were perinatal and malignancy and most common amongst non-survivors was a perinatal condition 
(Tables, Supplemental Digital Content 3 and 4). Gram-negative pathogens were isolated in 261/452 
(57.7%) of infections. The three most common isolates overall were S. aureus (19.3%), E. coli (17.9%) 
and Klebsiella spp. (12.2%). In total, 158 unique empiric antibiotic regimens were prescribed to 
patients (Table, Supplemental Digital Content 5). 25.1% (113/451) of patients had a discordant first 
empiric regimen (given within one day after blood culture). Expectedly this was slightly lower when a 
longer time frame of two days post-blood culture was considered (15.3%; 69/452).  
Discordant empiric antimicrobial therapy occurred in approximately equal proportions in Gram-
positive (15.7%, 30/191) and Gram-negative infections (14.9%, 39/261); however, a higher 
proportion of the deaths occurred in patients with Gram-negative pathogens of which Acinetobacter 
spp. and Serratia spp. had the highest mortality rates overall (4/14, 29% and 3/14, 23% respectively) 
(Table 2). Discordant regimens by pathogen and concordance of pathogens without fatalities are in 
Supplemental Digital Content 6 (table) and Supplemental Digital Content 7 (table) respectively.  
Due to a possible clinical reason for the subset of patients (n=34) not being started on any antibiotics 




(Table 3). These 34 patients started antibiotics within the first two days after blood culture and are 
included in the overall cohort (n=452). 
Overall, 35 children died (7.7%). Considering mortality by concordance, overall 23/383 (6.0%) of 
children died in the concordant group and 12/69 (17.4%) of children died in the discordant group 
(p=0.001). When considering only the first empiric regimen, 20/338 (5.9%) of children died in the 
concordant group and 15/113 (13.3%) of children died in the discordant group (p=0.011).  
Univariable Analysis  
In the unadjusted analysis, discordant empiric therapy in the first two days post blood culture was 
associated with a 3.3 increase in odds of 30-day mortality (95%CI:1.5-7.1, p=0.0011). Discordance in 
the first antibiotic regimen administered was associated with a 2.4 increase in odds of 30-day 
mortality (unadjusted, 95%CI:1.2–5.0, p= 0.0115). When excluding patients who did not receive 
antibiotics in the first day after blood culture (n=417), discordance of first antibiotic regimen was 
associated with 3.1 increase in odds of 30-day mortality (unadjusted, 95%CI:1.5–6.7, p=0.0018). 
Comorbidity, unit type, ventilation, infection type and pathogen type were also individually 
significantly associated with 30-day mortality (Table 4).  
Multivariable Analysis 
Variables associated with mortality in univariate analyses and those selected a priori (age and sex) 
were included in the logistic regression models. Ventilation status was not used due to strong 
association with unit type (P<0.001). Both a priori and final models are presented (Table 5). All 
adjusted models had a similar magnitude of association: the highest association between 
discordance and death occurred in the overall cohort (OR=3.1, p=0.010) and lowest occurring in the 
first empiric group (OR=2.5, p=0.023) when including patients not receiving any antibiotics in the 
first day after blood culture (Table 5).   
Discussion 
We found a three-fold increase in the odds of 30-day all-cause mortality associated with discordant 




receipt of concordant empiric antibiotics may contribute to improving clinical outcomes. When 
considering just empiric antibiotics in the first day after blood culture the association persisted and 
was stronger when excluding patients who did not start treatment until the second day post blood 
culture. This stronger association suggests that there may have been a clinical reason these patients 
were not started on treatment (e.g. delayed until further deterioration or further results were 
received). These patients were predominantly children without comorbidities being treated for CAI 
in a non-ICU setting and only accounted for 2/35 deaths. While our study did not include data on 
severity of illness this difference in association in first empiric antibiotics suggests that receipt of 
concordant early antibiotics has a greater impact for some patients, potentially those presenting 
with critical illness. The decrease in the proportion of patients receiving discordant treatment from 
the first to the second day of treatment suggests that several patients had treatment started or 
changed to a concordant regimen between one and two days after blood culture, potentially 
influenced by clinical factors in the absence of microbiological results.  
While previous adult studies show discordant antimicrobial therapy is associated with poorer 
outcomes, (1–3,15–21) there are very few studies examining the association between discordant 
antimicrobial therapy and poor outcomes in neonates and children. A recent neonatal sepsis cohort 
study in India found higher mortality rates among neonates with multidrug-resistant pathogens than 
those with sensitive isolates (13.4% vs. 9.4%, respectively).(22) A few other studies have shown 
similar associations between antimicrobial resistance and mortality and other adverse outcomes, 
(23–26) particularly in Gram-negative infections, infections due to ESBL-producing bacteria and 
those caused by carbapenem-non-susceptible Acinetobacter spp.(27–33) Generally, studies did not 
explicitly study the concordance of empiric antimicrobial therapy, but rather simply reported on the 
resistance profile of pathogens.  
The data in our study were voluntarily collected as one module of a large surveillance study and may 




do voluntary research and not representative of all hospital types in the included countries. We were 
unable to adjust for centre/country due to wide variation in number of patients enrolled in each.   
Clinical data were limited, meaning it was not possible to control for all possible confounders. 
Although we controlled for presence of a comorbidity, there was a wide range of comorbidity types 
amongst the patients who died, and we were unable to control for the severity of each comorbidity. 
Given the way perinatal conditions were classified, it is possible the number of patients with at least 
one comorbidity was underestimated as some perinatal comorbidities (e.g. asphyxia) might have 
been underestimated in preterm neonates. Overall the population in our study was quite 
heterogenous in presentation and covered a wide age range from a number of countries which may 
limit the ability to extrapolate our findings to specific paediatric sub-populations. However, given the 
limited data in this area particularly in paediatrics, our findings suggest that more research is needed 
to inform empiric prescribing regimens within specific sub-populations.  
Based on evidence that a higher burden of resistant infections occur in patients <1 year and HAI 
across all age groups are more commonly resistant, we controlled for HAI, comorbidity and 
age.(34,35) We calculated HAI as 2 or more calendar days after admission, however this may have 
overestimated the number of HAI since we were unable to calculate it in hours from admission. 
Although certain pathogens may be associated with mortality and specific comorbidities, our study 
was insufficiently powered to control for bacterial species, so we opted to control for Gram-stain as 
a proxy.  
We were very conservative with our definition of empiric treatment as the time from culture to full 
speciation and susceptibility is likely more than 2 days in many settings given microbiology capacity 
and laboratory result reporting systems. (5) The observed high proportion of discordance in the first 
two days after culture indicates that clinicians likely would not have had microbiology data available 
at that time. Some residual discordance is expected even after access to susceptibility results due to 
highly resistant pathogens or lack of access to broader-spectrum treatment.(36,37) Despite our 




stain) from microbiology to clinicians must have occurred in this period after culture because a 
reduction in discordance was observed between the first empiric and overall empiric cohort. We 
used site-reported SIR (susceptible, intermediate, resistant) for each bug-drug combination, 
however we used EUCAST interpretive algorithms to define concordance to empiric regimens. We 
were conservative with our definition of resistant (e.g. coding intermediate as resistant) to try to 
account for any possible differences in breakpoints between Clinical & Laboratory Standards 
Institute (CLSI) and EUCAST as some sites used CLSI standards for determining SIR, however 
interpretive criteria may differ between the two standards.(38)  
Even in high income settings it can take more than 50 hours from culture to speciation,(5) with 
longer timelines in the low and middle income country (LMIC) setting due to lack of microbiology 
resources.(36) Improving microbiology facilities, particularly in LMIC, to allow for timely processing 
and dissemination of results from microbiology labs to clinicians is important to improve targeted 
treatment and to allow for local resistance patterns to be incorporated into institution, national or 
regional treatment guidelines.(5,36,39) Larger studies in diverse hospital settings will need to be 
done to quantify the effect of early concordant treatment on survival.  
Currently, there is observed high use of broad-spectrum empiric antibiotics not reflecting WHO 
recommendations, suggesting that clinicians are responding to observed poor outcomes and high 
resistance rates.(8,9) This has implications for antimicrobial stewardship practices. A straightforward 
clinically applicable risk assessment, including age, unit type, HAI and other factors, could be one 
way to reduce empiric broad-spectrum prescribing without negatively impacting mortality.(40) Risk 
stratification could be used to as a stewardship strategy to identify patients at higher a priori risk of 
mortality who should be started on broader-spectrum therapy and de-escalated subsequently as 
well as patients at lower a priori risk who could be started on narrower-spectrum treatment. In 
order to comprehensively tackle antimicrobial resistance such a risk stratification guideline would 
need to be implemented alongside other measures including infection prevention and control 




Despite some limitations, our study indicates increased odds of mortality in neonates and children 
receiving discordant empiric antibiotic treatment for bloodstream infection in the first 2 days post 
blood culture. Our findings suggest that early concordant treatment could potentially reduce 
mortality in this population, perhaps with the largest expected impact in a subgroup of critically ill 
infants and children with co-morbidities and HAI. In order to achieve this and maintain appropriate 
levels of broad-spectrum prescribing, future studies will be needed to assess stratifying treatment 
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